-
Patent Agency Ranking
公开(公告)号：US20180235983A1
公开(公告)日：2018-08-23
申请号：US15552887
申请日：2016-02-25
Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
Inventor： Madhusudhan BOMMAGANI , Subhas Balaram BHOWMICK , Prashant KANE , Vaibhav DUBEY
CPC classification number: A61K31/65 , A61K9/0014 , A61K9/06 , A61K9/10 , A61K9/122 , A61K9/143 , A61K9/146
Abstract: The present invention relates to a method of preparing a nanoparticulate topical composition of a water soluble, water-susceptible active ingredient or its pharmaceutically acceptable salt, the method comprising steps of milling the water soluble, water-susceptible active ingredient or its salt, a wetting agent and a non-aqueous liquid vehicle to obtain a non-aqueous nanosuspension and converting the non-aqueous nanosuspension into a topical composition.
-
公开(公告)号：US20150290277A1
公开(公告)日：2015-10-15
申请号：US14750496
申请日：2015-06-25
Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY, LTD.
Inventor： Alok B. NAMDEO , Narayanaswamy SUBRAMANIAN , Subhas Balaram BHOWMICK
CPC classification number: A61K38/05 , A61K9/0019 , A61K9/19 , A61K31/407 , A61K31/4965 , A61K47/18 , A61K2300/00
Abstract: The present invention relates to a parenteral pharmaceutical composition comprising therapeutically effective amounts of N-(2-pyrazine) carbonyl-L-phenylalanine-L-leucine boronic acid or its salts or its derivatives and tromethamine wherein the composition is stable.
Abstract translation: 本发明涉及包含治疗有效量的N-（2-吡嗪）羰基-L-苯丙氨酸-L-亮氨酸硼酸或其盐或其衍生物和氨基丁三醇的肠胃外药物组合物，其中组合物是稳定的。
-
公开(公告)号：US20150290216A1
公开(公告)日：2015-10-15
申请号：US14691167
申请日：2015-04-20
Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY, LTD.
Inventor： Ajay Jaysingh KHOPADE , Arindam HALDER , Subhas Balaram BHOWMICK
IPC: A61K31/5575 , A61K47/10 , A61K47/44 , A61K47/14
CPC classification number: A61K31/5575 , A61K9/0048 , A61K9/1075 , A61K31/00 , A61K47/14
Abstract: The present invention relates to a pharmaceutical composition suitable for ophthalmic use comprising one or more prostaglandin derivatives or salts, a stabilizing amount of polyethylene glycol hydroxystearate and pharmaceutically acceptable vehicle.
Abstract translation: 本发明涉及适用于眼用的药物组合物，其包含一种或多种前列腺素衍生物或盐，稳定量的聚乙二醇羟基硬脂酸酯和药学上可接受的载体。
-
公开(公告)号：US20140030352A1
公开(公告)日：2014-01-30
申请号：US14045250
申请日：2013-10-03
Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
Inventor： Ajay Jaysingh KHOPADE , Subhas Balaram BHOWMICK , Natarajan ARULSUDAR
IPC: A61K9/10 , A61K9/08 , A61K9/14 , A61K31/337
CPC classification number: A61K9/10 , A61K9/08 , A61K9/1075 , A61K9/146 , A61K9/5138 , A61K9/5146 , A61K31/337
Abstract: The present invention provides a nanodispersion comprising nanoparticles having a mean size less than 300 nm dispersed in a vehicle comprising a water miscible solvent and water, said nanoparticles comprising one or more taxane derivative, a polymer and a surfactant comprising a mixture of fatty acids or its salts and sterol or its derivatives or its salts.
Abstract translation: 本发明提供纳米分散体，其包含分散在包含水混溶性溶剂和水的载体中的平均粒径小于300nm的纳米颗粒，所述纳米颗粒包含一种或多种紫杉烷衍生物，聚合物和包含脂肪酸或其混合物的混合物的表面活性剂 盐和甾醇或其衍生物或其盐。
-
公开(公告)号：US20180036243A1
公开(公告)日：2018-02-08
申请号：US15552966
申请日：2016-02-25
Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
Inventor： Madhusudhan BOMMAGANI , Subhas Balaram BHOWMICK , Prashant KANE , Vaibhav DUBEY
CPC classification number: A61K9/146 , A61K9/0014 , A61K9/06 , A61K9/10 , A61K9/122 , A61K31/65 , A61K47/14 , Y02A50/473
Abstract: The present invention relates to a nanoparticulate topical composition comprising (i) nanoparticles of a water soluble and water susceptible active ingredient or its pharmaceutically acceptable salt, having a particle size distribution such that 90% of the particles are less than 1000 nm, (ii) one or more wetting agent and (iii) a non-aqueous liquid vehicle, wherein the composition is free of water.The present invention also relates to a method of treating acne, rosacea, impetigo or a skin disease caused by a bacteria, by topical application of a nanoparticulate topical composition comprising nanoparticles of a water soluble and water susceptible active ingredient or its pharmaceutically acceptable salt, having a particle size distribution such that 90% of the particles are less than 1000 nm.
-
-
-
-
Search Results
5
records
(took 0.02 seconds)
